Literature DB >> 26847060

Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib.

Pavan Bachireddy1, Catherine J Wu2.   

Abstract

The clinical success of agents targeting the B-cell receptor signaling pathway in chronic lymphocytic leukemia (CLL) may also derive from disrupting the CLL microenvironment. Investigation of the immunomodulatory effects of these agents illuminates the unique immunobiology of CLL and highlights potential targets for dismantling the chronic inflammatory drive. See related article by Niemann et al., p. 1572. ©2016 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26847060      PMCID： PMC4818665          DOI： 10.1158/1078-0432.CCR-15-3106

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Authors:  Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

2.  A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.

Authors:  Davide Bagnara; Matthew S Kaufman; Carlo Calissano; Sonia Marsilio; Piers E M Patten; Rita Simone; Philip Chum; Xiao-Jie Yan; Steven L Allen; Jonathan E Kolitz; Sivasubramanian Baskar; Christoph Rader; Hakan Mellstedt; Hodjattallah Rabbani; Annette Lee; Peter K Gregersen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

3.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Authors:  Jason A Dubovsky; Kyle A Beckwith; Gayathri Natarajan; Jennifer A Woyach; Samantha Jaglowski; Yiming Zhong; Joshua D Hessler; Ta-Ming Liu; Betty Y Chang; Karilyn M Larkin; Matthew R Stefanovski; Danielle L Chappell; Frank W Frissora; Lisa L Smith; Kelly A Smucker; Joseph M Flynn; Jeffrey A Jones; Leslie A Andritsos; Kami Maddocks; Amy M Lehman; Richard Furman; Jeff Sharman; Anjali Mishra; Michael A Caligiuri; Abhay R Satoskar; Joseph J Buggy; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2013-07-25       Impact factor: 22.113

Review 4.  Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.

Authors:  John C Byrd; Jeffrey J Jones; Jennifer A Woyach; Amy J Johnson; Joseph M Flynn
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

5.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Authors:  Yair Herishanu; Patricia Pérez-Galán; Delong Liu; Angélique Biancotto; Stefania Pittaluga; Berengere Vire; Federica Gibellini; Ndegwa Njuguna; Elinor Lee; Lawrence Stennett; Nalini Raghavachari; Poching Liu; J Philip McCoy; Mark Raffeld; Maryalice Stetler-Stevenson; Constance Yuan; Richard Sherry; Diane C Arthur; Irina Maric; Therese White; Gerald E Marti; Peter Munson; Wyndham H Wilson; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

6.  Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia.

Authors:  Li Jia; Andrew Clear; Feng-Ting Liu; Janet Matthews; Nadiha Uddin; Aine McCarthy; Elena Hoxha; Catherine Durance; Sameena Iqbal; John G Gribben
Journal:  Blood       Date:  2014-01-24       Impact factor: 22.113

7.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Authors:  Jan A Burger; Alessandra Tedeschi; Paul M Barr; Tadeusz Robak; Carolyn Owen; Paolo Ghia; Osnat Bairey; Peter Hillmen; Nancy L Bartlett; Jianyong Li; David Simpson; Sebastian Grosicki; Stephen Devereux; Helen McCarthy; Steven Coutre; Hang Quach; Gianluca Gaidano; Zvenyslava Maslyak; Don A Stevens; Ann Janssens; Fritz Offner; Jiří Mayer; Michael O'Dwyer; Andrzej Hellmann; Anna Schuh; Tanya Siddiqi; Aaron Polliack; Constantine S Tam; Deepali Suri; Mei Cheng; Fong Clow; Lori Styles; Danelle F James; Thomas J Kipps
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

Review 8.  Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications.

Authors:  Yair Herishanu; Ben-Zion Katz; Andrew Lipsky; Adrian Wiestner
Journal:  Hematol Oncol Clin North Am       Date:  2013-04       Impact factor: 3.722

9.  Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.

Authors:  Carsten U Niemann; Sarah E M Herman; Irina Maric; Julio Gomez-Rodriguez; Angelique Biancotto; Betty Y Chang; Sabrina Martyr; Maryalice Stetler-Stevenson; Constance M Yuan; Katherine R Calvo; Raul C Braylan; Janet Valdez; Yuh Shan Lee; Deanna H Wong; Jade Jones; Clare Sun; Gerald E Marti; Mohammed Z H Farooqui; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2015-12-09       Impact factor: 12.531

10.  T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

Authors:  John C Riches; Jeffrey K Davies; Fabienne McClanahan; Rewas Fatah; Sameena Iqbal; Samir Agrawal; Alan G Ramsay; John G Gribben
Journal:  Blood       Date:  2012-12-17       Impact factor: 22.113
View more
  7 in total

1.  Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia.

Authors:  Mauricette Michallet; Peter Dreger; Mohamad Sobh; Linda Koster; Jennifer Hoek; Ariane Boumendil; Christof Scheid; Christopher P Fox; Gerald Wulf; William Krüger; Michel van Gelder; Paolo Corradini; Domenico Russo; Jakob Passweg; Hélène Schoemans; Wolfgang Bethge; Nicolaas Schaap; Jan Cornelissen; Paul Browne; Nadira Durakovic; Lutz Muller; Silvia Montoto; Nicolaus Kroger; Johannes Schetelig
Journal:  Bone Marrow Transplant       Date:  2019-11-07       Impact factor: 5.483

2.  Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

Authors:  Christine E Ryan; Bita Sahaf; Aaron C Logan; Susan O'Brien; John C Byrd; Peter Hillmen; Jennifer R Brown; Martin J S Dyer; Anthony R Mato; Michael J Keating; Samantha Jaglowski; Fong Clow; Andrew R Rezvani; Lori Styles; Steven E Coutre; David B Miklos
Journal:  Blood       Date:  2016-11-01       Impact factor: 22.113

3.  Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.

Authors:  Carsten U Niemann; Helena I Mora-Jensen; Eman L Dadashian; Fanny Krantz; Todd Covey; Shih-Shih Chen; Nicholas Chiorazzi; Raquel Izumi; Roger Ulrich; Brian J Lannutti; Adrian Wiestner; Sarah E M Herman
Journal:  Clin Cancer Res       Date:  2017-06-23       Impact factor: 12.531

4.  Low Density Lipoproteins Amplify Cytokine-signaling in Chronic Lymphocytic Leukemia Cells.

Authors:  Lindsay McCaw; Yonghong Shi; Guizhi Wang; You-Jun Li; David E Spaner
Journal:  EBioMedicine       Date:  2016-11-30       Impact factor: 8.143

Review 5.  Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies.

Authors:  Ilenia Sana; Maria Elena Mantione; Piera Angelillo; Marta Muzio
Journal:  Front Oncol       Date:  2021-04-01       Impact factor: 6.244

6.  Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.

Authors:  Bola S Hanna; Haniyeh Yazdanparast; Yasmin Demerdash; Philipp M Roessner; Ralph Schulz; Peter Lichter; Stephan Stilgenbauer; Martina Seiffert
Journal:  Haematologica       Date:  2021-04-01       Impact factor: 9.941

7.  Machine learning can identify newly diagnosed patients with CLL at high risk of infection.

Authors:  Rudi Agius; Christian Brieghel; Michael A Andersen; Alexander T Pearson; Bruno Ledergerber; Alessandro Cozzi-Lepri; Yoram Louzoun; Christen L Andersen; Jacob Bergstedt; Jakob H von Stemann; Mette Jørgensen; Man-Hung Eric Tang; Magnus Fontes; Jasmin Bahlo; Carmen D Herling; Michael Hallek; Jens Lundgren; Cameron Ross MacPherson; Jan Larsen; Carsten U Niemann
Journal:  Nat Commun       Date:  2020-01-17       Impact factor: 14.919
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.